EMFAT
CLDX icon

Emerald Mutual Fund Advisers Trust’s Celldex Therapeutics CLDX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-243,795
Closed -$8.29M – 218
2024
Q3 		$8.29M Buy
243,795
+116,832
+92% +$4.45M 0.43% 78
2024
Q2 		$4.7M Hold
126,963
– – 0.25% 105
2024
Q1 		$5.33M Buy
+126,963
New +$5.21M 0.28% 105
2013
Q4 		– Sell
-14,894
Closed -$7.92M – 212
2013
Q3 		$7.92M Buy
14,894
+375
+3% +$129K 1.09% 24
2013
Q2 		$3.4M Buy
+14,519
New +$2.86M 0.58% 69

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CLDX Position: Q4 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 243,795 shares — an estimated $8.29M sold.

Emerald Mutual Fund Advisers Trust first reported a position in CLDX in Q2 2013 and held it in 5 quarters. The position peaked at $8.29M in Q3 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Emerald Mutual Fund Advisers Trust reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 243,795 Celldex Therapeutics shares in Q4 2024, an estimated $8.29M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Celldex Therapeutics in Q2 2013 and held it in 5 quarters.
  • Emerald Mutual Fund Advisers Trust's Celldex Therapeutics position peaked at $8.29M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2024, filed 14 Feb 2025.